MIRM | Mirum Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	40.83 - 42.05
52 Week Range	23.14 - 45.23
Beta	0.95
Implied Volatility	88.29%
IV Rank	65.50%
Day's Volume	215,183
Average Volume	753,096
Shares Outstanding	47,707,200
Market Cap	1,961,720,064
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-07-18

Valuation
Profitability
Growth
Health
P/E Ratio	-17.80
Forward P/E Ratio	N/A
EPS	-2.31
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	278
Country	USA
Website	MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

MIRM's peers: ARQT, CDMO, FULC, HUMA, IMCR, KALV, LQDA, LRMR, LYRA, TERN, AMLX, ABOS, INZY, XFOR, DAWN, MLTX, APLS, BPMC, CERE, ICVX, VECT, MRNS, OMER, RCKT, RGNX, YMAB

*Chart delayed

Analyzing fundamentals for MIRM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see MIRM Fundamentals page.

Watching at MIRM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MIRM Technicals page.